Allogeneic peripheral blood stem celll transplantation for the treatment of chronic active Epstein-Barr virus infection

Nobuharu Fujii, K. Takenaka, A. Hiraki, Yoshinobu Maeda, K. Ikeda, K. Shinagawa, A. Ashiba, M. Munemasa, K. Sunami, Y. Hiramatsu, F. Ishimaru, K. Niiya, Tadashi Yoshino, M. Harada

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The prognosis of chronic active Epstein-Barr virus infection (CAEBV) is very poor. We describe a 24-year-old male with severe CAEBV who was treated with allogeneic peripheral blood stem cell transplantation (allo-PBSCT). On admission, EBER-1 in lymphocytes infiltrating the liver, EBV-DNA in peripheral blood mononuclear cells (PBMC) and monoclonal NK cell proliferation were confirmed. After unsuccessful chemotherapy, he received an allo-PBSCT from his HLA-identical sister. Although he died of pulmonary hemorrhage on day +19, EBV-DNA was undetectable by PCR in PBMC, and the post-mortem liver showed no EBER-1-positive lymphocytes. This experience suggests that EBV-positive lymphocytes in CAEBV may be eradicated by allo-PBSCT, thereby raising the possibility of a new treatment modality.

Original languageEnglish
Pages (from-to)805-808
Number of pages4
JournalBone Marrow Transplantation
Volume26
Issue number7
Publication statusPublished - 2000

Fingerprint

Peripheral Blood Stem Cell Transplantation
Epstein-Barr Virus Infections
Human Herpesvirus 4
Transplantation
Lymphocytes
Blood Cells
Liver
DNA
Natural Killer Cells
Therapeutics
Cell Proliferation
Hemorrhage
Drug Therapy
Polymerase Chain Reaction
Lung
Epstein-Barr virus encoded RNA 1

Keywords

  • Allogeneic peripheral blood stem cell transplantation
  • Chronic active Epstein-Barr virus infection
  • EBV-specific CTL
  • Myeloablative conditioning regimen

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Allogeneic peripheral blood stem celll transplantation for the treatment of chronic active Epstein-Barr virus infection. / Fujii, Nobuharu; Takenaka, K.; Hiraki, A.; Maeda, Yoshinobu; Ikeda, K.; Shinagawa, K.; Ashiba, A.; Munemasa, M.; Sunami, K.; Hiramatsu, Y.; Ishimaru, F.; Niiya, K.; Yoshino, Tadashi; Harada, M.

In: Bone Marrow Transplantation, Vol. 26, No. 7, 2000, p. 805-808.

Research output: Contribution to journalArticle

Fujii, N, Takenaka, K, Hiraki, A, Maeda, Y, Ikeda, K, Shinagawa, K, Ashiba, A, Munemasa, M, Sunami, K, Hiramatsu, Y, Ishimaru, F, Niiya, K, Yoshino, T & Harada, M 2000, 'Allogeneic peripheral blood stem celll transplantation for the treatment of chronic active Epstein-Barr virus infection', Bone Marrow Transplantation, vol. 26, no. 7, pp. 805-808.
Fujii, Nobuharu ; Takenaka, K. ; Hiraki, A. ; Maeda, Yoshinobu ; Ikeda, K. ; Shinagawa, K. ; Ashiba, A. ; Munemasa, M. ; Sunami, K. ; Hiramatsu, Y. ; Ishimaru, F. ; Niiya, K. ; Yoshino, Tadashi ; Harada, M. / Allogeneic peripheral blood stem celll transplantation for the treatment of chronic active Epstein-Barr virus infection. In: Bone Marrow Transplantation. 2000 ; Vol. 26, No. 7. pp. 805-808.
@article{2cc970c9983944ae837b3e84f6b8991c,
title = "Allogeneic peripheral blood stem celll transplantation for the treatment of chronic active Epstein-Barr virus infection",
abstract = "The prognosis of chronic active Epstein-Barr virus infection (CAEBV) is very poor. We describe a 24-year-old male with severe CAEBV who was treated with allogeneic peripheral blood stem cell transplantation (allo-PBSCT). On admission, EBER-1 in lymphocytes infiltrating the liver, EBV-DNA in peripheral blood mononuclear cells (PBMC) and monoclonal NK cell proliferation were confirmed. After unsuccessful chemotherapy, he received an allo-PBSCT from his HLA-identical sister. Although he died of pulmonary hemorrhage on day +19, EBV-DNA was undetectable by PCR in PBMC, and the post-mortem liver showed no EBER-1-positive lymphocytes. This experience suggests that EBV-positive lymphocytes in CAEBV may be eradicated by allo-PBSCT, thereby raising the possibility of a new treatment modality.",
keywords = "Allogeneic peripheral blood stem cell transplantation, Chronic active Epstein-Barr virus infection, EBV-specific CTL, Myeloablative conditioning regimen",
author = "Nobuharu Fujii and K. Takenaka and A. Hiraki and Yoshinobu Maeda and K. Ikeda and K. Shinagawa and A. Ashiba and M. Munemasa and K. Sunami and Y. Hiramatsu and F. Ishimaru and K. Niiya and Tadashi Yoshino and M. Harada",
year = "2000",
language = "English",
volume = "26",
pages = "805--808",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Allogeneic peripheral blood stem celll transplantation for the treatment of chronic active Epstein-Barr virus infection

AU - Fujii, Nobuharu

AU - Takenaka, K.

AU - Hiraki, A.

AU - Maeda, Yoshinobu

AU - Ikeda, K.

AU - Shinagawa, K.

AU - Ashiba, A.

AU - Munemasa, M.

AU - Sunami, K.

AU - Hiramatsu, Y.

AU - Ishimaru, F.

AU - Niiya, K.

AU - Yoshino, Tadashi

AU - Harada, M.

PY - 2000

Y1 - 2000

N2 - The prognosis of chronic active Epstein-Barr virus infection (CAEBV) is very poor. We describe a 24-year-old male with severe CAEBV who was treated with allogeneic peripheral blood stem cell transplantation (allo-PBSCT). On admission, EBER-1 in lymphocytes infiltrating the liver, EBV-DNA in peripheral blood mononuclear cells (PBMC) and monoclonal NK cell proliferation were confirmed. After unsuccessful chemotherapy, he received an allo-PBSCT from his HLA-identical sister. Although he died of pulmonary hemorrhage on day +19, EBV-DNA was undetectable by PCR in PBMC, and the post-mortem liver showed no EBER-1-positive lymphocytes. This experience suggests that EBV-positive lymphocytes in CAEBV may be eradicated by allo-PBSCT, thereby raising the possibility of a new treatment modality.

AB - The prognosis of chronic active Epstein-Barr virus infection (CAEBV) is very poor. We describe a 24-year-old male with severe CAEBV who was treated with allogeneic peripheral blood stem cell transplantation (allo-PBSCT). On admission, EBER-1 in lymphocytes infiltrating the liver, EBV-DNA in peripheral blood mononuclear cells (PBMC) and monoclonal NK cell proliferation were confirmed. After unsuccessful chemotherapy, he received an allo-PBSCT from his HLA-identical sister. Although he died of pulmonary hemorrhage on day +19, EBV-DNA was undetectable by PCR in PBMC, and the post-mortem liver showed no EBER-1-positive lymphocytes. This experience suggests that EBV-positive lymphocytes in CAEBV may be eradicated by allo-PBSCT, thereby raising the possibility of a new treatment modality.

KW - Allogeneic peripheral blood stem cell transplantation

KW - Chronic active Epstein-Barr virus infection

KW - EBV-specific CTL

KW - Myeloablative conditioning regimen

UR - http://www.scopus.com/inward/record.url?scp=0033754421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033754421&partnerID=8YFLogxK

M3 - Article

VL - 26

SP - 805

EP - 808

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 7

ER -